Zobrazeno 1 - 10
of 179
pro vyhledávání: ''
Autor:
Chuan Zheng, Ding-Kun Zhang, Fang Wang, Yunzhen Shi, Xi-Chuan Wei, Ruifang Yuan, Jinming Zhang, Chuanhong Luo, Ming Yang, Qi Hu, Yi Wu, Jinhui Yang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background:Zanthoxylum schinifolium is a common herbal medicine in Southwest China. It is also a condiment commonly used in many families. In Chinese folk medicine, Z. schinifolium is considered to have the effect of relieving migraine, but there is
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Phenotype screening has become an important tool for the discovery of active components in traditional Chinese medicine. Anshen Buxin Six Pills (ASBX) are a traditional Mongolian medicine used for the treatment of neurosis in clinical settings. Howev
Autor:
Muhan Jing, Shanshan Wang, Ding Li, Zeyu Wang, Ziwen Li, Yichen Lu, Tong Sun, Chen Qiu, Fang Chen, Haijuan Yu, Wei Zhang
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients’ a
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer (NSCLC) in China. The purpose of this study was to determine whether u
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background: Although the predominant airway inflammation in chronic obstructive pulmonary disease (COPD) is neutrophilic, approximately 20–40% of COPD patients present with eosinophilic airway inflammation. Compared with non-eosinophilic COPD patie
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Remote ischemic preconditioning (RIPC) is one of the most effective approaches to attenuate tissue injury caused by severe ischemia-reperfusion (I/R). Experimental studies have demonstrated that RIPC is capable of producing a protective effect not on
Autor:
KM Roach, E Castells, K Dixon, S Mason, G Elliott, H Marshall, MA Poblocka, S Macip, M Richardson, L Khalfaoui, P Bradding
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved treatments for IPF but have limited efficacy and their mechanisms
Autor:
Gonzalo Villapalos-García, Pablo Zubiaur, Marcos Navares-Gómez, Miriam Saiz-Rodríguez, Gina Mejía-Abril, Samuel Martín-Vílchez, Manuel Román, Dolores Ochoa, Francisco Abad-Santos
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia (BPH). Despite being more effective than monotherapies, they produce frequent adverse drug reactions (ADRs). Institutions su
Autor:
Shuiqing Huang, Guo-sheng Liu, Shasha Han, Chuan Nie, Jianwen Xiang, Xian-qiong Luo, Hongping Li, Weiming Ou, Longkai He, Jing-bo Jiang, Jiamin Gan
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Objectives: Probenecid is an anion transport inhibitor, which, according to the connectivity map (CMap; a biological application database), interferes with hypoxia-induced gene expression changes in retinal vascular endothelial cells (ECs). Here, we
Autor:
Gabrielle M. Henriques, Alexia Anjos-Santos, Isa R. S. Rodrigues, Victor Nascimento-Rocha, Henrique S. Reis, Matheus Libarino-Santos, Thaísa Barros-Santos, Thais S. Yokoyama, Natalia B. Bertagna, Cristiane A. Favoretto, Célia R. G. Moraes, Fábio C. Cruz, Paulo C. R. Barbosa, Eduardo A. V. Marinho, Alexandre J. Oliveira-Lima, Laís F. Berro
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Ibogaine is a psychedelic extracted from the plant Tabernanthe iboga Baill. (Apocynaceae), natural from Africa, and has been proposed as a potential treatment for substance use disorders. In animal models, ibogaine reduces ethanol self-administration